Postherpetic Neuralgia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Postherpetic Neuralgia – Drugs In Development, 2024 report and make more profitable business decisions.
Postherpetic neuralgia (PHN) emerges as the predominant long-term consequence of varicella-zoster virus (VZV) reactivation, commonly known as herpes zoster or shingles. VZV, responsible for childhood varicella (chickenpox), historically affected the majority of American adults before widespread vaccination. While future generations may experience lower rates of herpes zoster and PHN, the latter remains clinically significant. PHN diagnosis heavily relies on history and physical examination, complemented by laboratory tests and targeted imaging for atypical presentations. Prevention involves identifying high-risk populations for VZV contraction and administering vaccines. Early recognition and treatment of acute HZ infection, along with symptom management using multimodal approaches, constitute essential strategies. Despite evolving evidence, prevention is crucial, given PHN’s often refractory nature, with many sufferers achieving only temporary relief despite comprehensive therapy.
The Postherpetic Neuralgia drugs in development market research report provide comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Postherpetic Neuralgia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Postherpetic Neuralgia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Postherpetic Neuralgia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Postherpetic Neuralgia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Achelios Therapeutics IncAllodynic Therapeutics LLC
Andros Pharmaceuticals Co Ltd
Avecho Biotechnology Ltd
Cellix Bio Pvt Ltd
Exodos Life Sciences Limited Partnership
Grunenthal GmbH
Hefei Cosource Pharmaceutical Inc
Incannex Healthcare Ltd
Lexicon Pharmaceuticals Inc
Maruho Co Ltd
Medifron DBT Co Ltd
MEDRx Co Ltd
NanoViricides Inc
Patagonia Pharmaceuticals LLC
PharmaTher Holdings Ltd
Samik Pharmaceutical Co Ltd
Scientus Pharma Inc
Sichuan Haisco Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Postherpetic Neuralgia reports